Rethink Obesity^® In Practice is an educational program developed and supported by Novo Nordisk to help in the management of people living with overweight and obesity – this is not a substitute for medical advice.

Reporting suspected adverse effects of medicinal products and devices is important as it allows continued monitoring of the benefit-risk balance of the product. Healthcare professionals are asked to report any suspected adverse effects related to Novo Nordisk products to: Novo Nordisk at report a side effect or TGA at reporting problems

AU23OB00100. April 2024.